Cromos Pharma successfully completes enrollment for a Phase II COVID-19 vaccine clinical trial

Cromos Pharma today (Thursday, 16 September, 2021) announced that it has successfully completed recruitment for a Phase II COVID-19 vaccine clinical trial. 

Cromos Pharma committed to supporting clinical research into Alzheimer's disease

This September Cromos Pharma is highlighting World Alzheimer’s Month. Read our article on Alzheimer's disease and brain health.

5 key takeaways from World Orphan Drug Congress USA

Cromos Pharma’s US BDD Nicole Brenna attended World Orphan Drug Congress USA (August 25-27, 2021) in Maryland. It was Cromos Pharma’s first in-person conference since the outbreak of the COVID-19 pandemic. Read Nicole’s 5 key takeaways from the event.


Cromos Pharma's Patient Portal now available in multiple languages

As part of our ongoing commitment to ensuring patients are well informed about their role in the clinical trials process, Cromos Pharma has added information in multiple languages. At our patients portal, you will now find this information in English, Polish, Russian, Ukranian, Georgian, Czech, and Hungarian. 

Getting ready for full implementation of the EU Clinical Trial Regulation

The countdown is on for the European Union (EU) Clinical Trial Regulation (Regulation (EU) No 536/2014) (CTR) with a go-live date of 31 January 2022. The implementation of the CTR will bring about significant changes to the way clinical trials are conducted in the EU. In this article Cromos Pharma outlines some of the requirements for sponsors.

Cromos Pharma on rare disease drug development

An estimated 475 million people are affected by rare disease worldwide, 50% of these are children and only 5% of people with a rare disease have a treatment. This represents a significant unmet medical need. Rare disease clinical trials involve challenges above and beyond those encountered for large scale clinical studies for more common diseases. 
See more